Investegate announcements from Tessa Therapeutics Ltd, Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform
Presentations to feature clinical data from a Phase II CD30 CAR-T therapy study and a Phase I CD30 CAR-EBVST therapy study targeting lymphomasSINGAPORE, Nov. 03, 2021 (GLOBE NEWSWIRE) Tessa Therapeutics
(0)
Data to be Presented Today at the ASGCT 24th Annual Meeting Demonstrated No Dose-Limiting Toxicity with Encouraging Clinical Activity in First 5 Patients Treated; Final Data Readout Expected by End of 2021
BEDMINSTER, N.J. and SINGAPORE, May 14, 2021) testing TT11X in patients with CD30+ lymphomas. The results will be presented today at the 24
th Annual Meeting of American Society of Gene and Cell Therapy (ASGCT 2021).
The presentation at ASGCT 2021 will highlight data from six patients treated with the therapy. The results demonstrated a favorable safety profile with encouraging clinical activity even at lower dose levels in heavily pre-treated relapsed / refractory (R/R) CD30+ lymphoma patients. The dataset includes three patients dosed at the lowest dosing level (4 × 10
(1)
BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/
Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the successful completion of dosing of the first patient cohort (n=3) in a Phase I dose escalation study, evaluating the safety and efficacy of Tessa s TT11X - Allogeneic CD30-CAR Epstein Barr Virus Specific T-cell (EBVST) therapy.
The Phase 1 study being conducted at Baylor College of Medicine aims to enroll up to 18 patients with CD30+ lymphoma across three dose levels. Study objectives are to evaluate safety and efficacy and establish dosing for the next phase. TT11X has been administered to three patients so far at Houston Methodist Hospital with a favorable safety profile. The therapy has been well tolerated with no evidence of GVHD or any severe adverse events associated with allogeneic therapies,